Myeloproliferative neoplasm

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

34Recruiting trials

Regulatory Watchboard

10 events

Jun 2026Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

Brigham and Women's Hospital — PHASE1

TrialNOT YET RECRUITING

May 2026Pacritinib With Aza for Upfront Myelodysplastic Syndrome

Thomas Jefferson University — PHASE1, PHASE2

TrialNOT YET RECRUITING

Mar 2026Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Incyte Corporation — PHASE1

TrialRECRUITING

Mar 2026Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

University of Washington — PHASE2

TrialRECRUITING

Mar 2026Doxycycline vs. Macrolide for MRMP (DOMINO)

Young June Choe — PHASE4

TrialNOT YET RECRUITING

Feb 2026Exercise Training in Patients With Myeloproliferative Neoplasms

Hannover Medical School — NA

TrialNOT YET RECRUITING

Feb 2026Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center — PHASE2

TrialRECRUITING

Feb 2026Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

PharmaEssentia — PHASE4

TrialNOT YET RECRUITING

Dec 2025Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

University Hospital, Bordeaux — NA

TrialRECRUITING

Aug 2025A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI) — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Agrylin

Takeda Development Center Americas, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Agrylin

(Anagrelide)Orphan drugstandard

Takeda Development Center Americas, Inc.

12.1 Mechanism of Action The precise mechanism by which anagrelide reduces blood platelet count is unknown. In cell culture studies, anagrelide suppre...

View full treatment details on disease page →

Clinical Trial Landscape

34 active trials

2Phase 3

8Phase 2

4Phase 1

4N/A

15Unknown

1PHASE1, PHASE2

34Total recruiting

Search clinical trials for Myeloproliferative neoplasm →

Recent News & Research

No recent news articles indexed yet for Myeloproliferative neoplasm.
Search PubMed for Myeloproliferative neoplasm →

Browse all Myeloproliferative neoplasm news →

Specialist Network

Top 6 by expertise

Jean-Jacques Kiladjian

(France) Clinical Investigations Center, Saint-Louis Hospital, Paris, France

Score 421 trial3 pubs

Claire Harrison

Acting on behalf of the Sponsor (UK), Guy's Hospital, London, UK, SE1 9RT

Score 401 trial24 pubs

Hagop Kantarjian, MD, MD

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 397 trials

Naveen Pemmaraju, M.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 383 trials10 pubs

Gabriela Hobbs, MD, MD

Massachusetts General Hospital

📍 BOSTON, MA

Score 384 trials1 pub

Rachel B. Salit, MD

Fred Hutch/University of Washington Cancer Consortium

📍 SEATTLE, WA

Score 374 trials

View all Myeloproliferative neoplasm specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles